CONDITION AND RESULTS OF OPERATIONS The following discussion analysis financial condition AbbVie Inc AbbVie company September 30 2017 December 31 2016 results operations three nine months ended September 30 2017 2016 This commentary read conjunction condensed consolidated financial statements accompanying notes appearing Item 1 Financial Statements Supplementary Data EXECUTIVE OVERVIEWCompany OverviewAbbVie global research-based biopharmaceutical company formed 2013 following separation Abbott Laboratories Abbott AbbVie mission use expertise dedicated people unique approach innovation develop market advanced therapies address world complex serious diseases AbbVie products focused treating conditions chronic autoimmune diseases rheumatology gastroenterology dermatology oncology including blood cancers virology including hepatitis C HCV human immunodeficiency virus HIV neurological disorders Parkinson disease multiple sclerosis metabolic diseases including thyroid disease complications associated cystic fibrosis well serious health conditions AbbVie also pipeline promising new medicines across important medical specialties immunology virology oncology neurology additional targeted investment cystic fibrosis women health.AbbVie products generally sold worldwide directly wholesalers distributors government agencies health care facilities specialty pharmacies independent retailers AbbVie-owned distribution centers public warehouses In United States AbbVie distributes pharmaceutical products principally independent wholesale distributors sales directly pharmacies patients Outside United States sales made either directly customers distributors depending market served Certain products co-marketed co-promoted companies AbbVie approximately 29,000 employees AbbVie operates one business segment pharmaceutical products.2017 Strategic ObjectivesAbbVie mission innovation-driven patient-focused specialty biopharmaceutical company capable achieving top-tier financial performance outstanding execution consistent stream innovative new medicines AbbVie intends continue advance mission number ways including growing revenues continued strong performance existing portfolio on-market products including flagship brands HUMIRA IMBRUVICA well growth pipeline products ii expanding operating margins iii continued investment pipeline support opportunities immunology oncology virology neurology well continued investment key on-market products iv augmentation pipeline concerted focus strategic licensing acquisition partnering activity focus identifying compelling programs fit AbbVie strategic criteria v returning cash shareholders via dividends share repurchases In addition AbbVie anticipates several regulatory submissions key data readouts key clinical trials next twelve months Financial ResultsThe company's financial performance nine months ended September 30 2017 included delivering worldwide net revenues 20.5 billion operating earnings 7.8 billion diluted earnings per share 3.27 Worldwide net revenues grew 9 constant currency basis driven primarily continued strength HUMIRA revenue growth related IMBRUVICA revenue growth key products including Creon Duodopa These increases partially offset decline net revenues HCV product VIEKIRA.Diluted earnings per share 3.27 nine months ended September 30 2017 included following after-tax costs 606 million related amortization intangible assets ii 546 million change fair value contingent consideration liabilities iii milestone payments 68 million iv litigation reserve charges 65 million v acquisition related costs 49 million vi 15 million acquired in-process research development IPR&D Additionally financial results nine months ended September 30 2017 reflected continued added funding support AbbVie emerging mid late-stage pipeline assets continued investment AbbVie growth brands.2017 Form 10-Q 26The company generated cash flows operations 7.4 billion nine months ended September 30 2017 AbbVie utilized continue enhance pipeline licensing collaboration activities pay cash dividends stockholders 3.1 billion repurchase approximately 7.8 million shares 500 million open market In September 2017 AbbVie board directors declared quarterly cash dividend 0.64 per share common stock payable November 2017 In October 2017 company announced board directors declared increase company's quarterly cash dividend 0.64 per share 0.71 per share beginning dividend payable February 2018 This reflects increase approximately 11 previous quarterly rate.In addition financial results AbbVie continued advance augment pipeline described heading Research Development Research DevelopmentResearch innovation cornerstones AbbVie business global biopharmaceutical company AbbVie long-term success depends great extent ability continue discover develop innovative pharmaceutical products acquire collaborate compounds currently development biotechnology pharmaceutical companies.AbbVie pipeline currently includes 60 compounds indications clinical development individually collaboration license agreements focused important medical specialties immunology oncology virology neurology along targeted investments cystic fibrosis women health Of programs 30 mid late-stage development The following sections summarize transitions significant programs Phase 2 development Phase 3 development well developments significant Phase 3 registration programs AbbVie expects multiple Phase 2 programs transition Phase 3 programs next twelve months.Significant Programs DevelopmentsImmunologyUpadacitinib In June 2017 AbbVie announced top-line results Phase 3 SELECT-NEXT clinical trial evaluating upadacitinib ABT-494 company selective JAK1 inhibitor currently late-stage development rheumatoid arthritis RA met primary ranked secondary endpoints patients moderate severe RA adequately respond treatment conventional synthetic disease modifying anti-rheumatic drugs DMARDs The safety profile upadacitinib consistent previously reported Phase 2 trials new safety signals detected In September 2017 AbbVie announced top-line results Phase 3 SELECT-BEYOND clinical trial evaluating upadacitinib met primary ranked secondary endpoints patients moderate severe RA adequately respond intolerant treatment biologic DMARDs The safety profile upadacitinib consistent previously reported Phase 2 trials Phase 3 SELECT-NEXT clinical trial new safety signals detected.Risankizumab In October 2017 AbbVie announced top-line results three Phase 3 clinical trials evaluating risankizumab investigational interleukin-23 IL-23 inhibitor 12-week dosing compared ustekinumab adalimumab met co-primary ranked secondary endpoints treatment patients moderate severe chronic plaque psoriasis The safety profile consistent previously reported studies new safety signals detected across three studies.2017 Form 10-Q 27OncologyIMBRUVICA In January 2017 AbbVie announced U.S Food Drug Administration FDA approved IMBRUVICA treatment patients relapsed/refractory marginal zone lymphoma MZL require systemic therapy received least one prior anti-CD20-based therapy This indication approved accelerated approval based overall response rate ORR continued approval may contingent upon verification description clinical benefit confirmatory trial MZL slow-growing form non-Hodgkin's lymphoma In August 2017 AbbVie announced FDA approved IMBRUVICA treatment adult patients chronic graft-versus-host-disease cGVHD failure one lines systemic therapy IMBRUVICA first therapy specifically approved adults cGVHD severe potentially life-threatening consequence stem cell bone marrow transplant This marks sixth U.S disease indication IMBRUVICA since medication's initial approval 2013 first approved indication outside cancer.Venetoclax In February 2017 AbbVie initiated Phase 3 clinical trial study safety efficacy venetoclax combination azacitidine untreated treatment-na elderly subjects acute myeloid leukemia AML ineligible standard induction therapy high-dose chemotherapy In May 2017 AbbVie initiated Phase 3 clinical trial evaluate venetoclax co-administered low dose cytarabine LDAC improves overall survival OS versus LDAC placebo treatment na subjects AML In September 2017 AbbVie announced top-line results Phase 3 MURANO clinical trial evaluating venetoclax tablets combination Rituxan rituximab met primary endpoint prolonged progression-free survival compared bendamustine combination Rituxan patients relapsed/refractory chronic lymphocytic leukemia.Rova-T In February 2017 AbbVie initiated Phase 3 clinical trial evaluate efficacy Rova-T maintenance therapy following first-line platinum based chemotherapy participants extensive stage small cell lung cancer SCLC In April 2017 AbbVie initiated Phase 3 clinical trial evaluate Rova-T compared topotecan subjects advanced metastatic SCLC high levels delta-like protein 3 first disease progression following front-line platinum-based chemotherapy.Veliparib In April 2017 AbbVie announced two Phase 3 studies evaluating veliparib investigational oral poly adenosine diphosphate-ribose polymerase PARP inhibitor combination chemotherapy meet primary endpoints The studies evaluated veliparib combination carboplatin paclitaxel patients squamous non-small cell lung cancer NSCLC triple negative breast cancer TNBC Ongoing Phase 3 studies include non-squamous non-small cell lung cancer BRCA1/2 breast cancer ovarian cancer.Virology/Liver Disease In February 2017 AbbVie announced European Committee Medicinal Products Human Use CHMP granted positive opinion shorter eight-week treatment VIEKIRAX ombitasvir/paritaprevir/ritonavir tablets EXVIERA dasabuvir tablets option previously untreated adult patients genotype 1b chronic HCV minimal moderate fibrosis In July 2017 AbbVie announced European Commission granted marketing authorization MAVIRET glecaprevir/pibrentasvir once-daily ribavirin-free treatment adults HCV infection across major genotypes GT1-6 MAVIRET also indicated patients specific treatment challenges including compensated 2017 Form 10-Q 28cirrhosis across major genotypes previously limited treatment options patients severe chronic kidney disease CKD genotype 3 chronic HCV infection In August 2017 AbbVie announced FDA approved MAVYRET glecaprevir/pibrentasvir treatment patients chronic HCV genotype 1-6 infection without cirrhosis compensated cirrhosis Child-Pugh A MAVYRET also indicated treatment adult patients HCV genotype 1 infection previously treated regimen containing HCV NS5A inhibitor NS3/4A protease inhibitor MAVYRET/MAVIRET new 8-week pan-genotypic treatment patients without cirrhosis new treatment.Other In September 2017 AbbVie announced submitted New Drug Application FDA elagolix investigational orally administered gonadotropin-releasing hormone GnRH antagonist evaluated management endometriosis associated pain In October AbbVie granted priority review elagolix FDA.For comprehensive discussion AbbVie products pipeline see company Annual Report Form 10-K year ended December 31 2016 RESULTS OF OPERATIONSNet Revenues The comparisons presented constant currency rates reflect comparative local currency net revenues prior year foreign exchange rates This measure provides information change net revenues assuming foreign currency exchange rates changed prior current periods AbbVie believes non-GAAP measure change net revenues constant currency rates used conjunction GAAP measure change net revenues actual currency rates may provide complete understanding company operations facilitate analysis company results operations particularly evaluating performance one period another Three months endedSeptember 30 Percent change Nine months endedSeptember 30 Percent change At actual currency rates At constant currency rates At actual currency rates At constant currency rates(dollars millions 2017 2016 20172016 United States $4,586 $4,081 12.4 12.4 13,284 $11,695 13.6 13.6%International 2,409 2,351 2.4 0.3 7,193 7,147 0.6 1.0%Net revenues $6,995 $6,432 8.8 8.1 20,477 $18,842 8.7 8.8%2017 Form 10-Q 29The following table details AbbVie worldwide net revenues Three months endedSeptember 30 Percent change Nine months endedSeptember 30 Percent change At actual currency rates At constant currency rates At actual currency rates At constant currency rates(dollars millions 2017 2016 2017 2016 HUMIRA United States $3,151 $2,647 19.1 19.1 9,048 $7,554 19.8 19.8 %International 1,550 1,413 9.7 6.8 4,487 4,232 6.0 6.8 %Total $4,701 $4,060 15.8 14.8 13,535 $11,786 14.8 15.1 %IMBRUVICA United States $574 $437 31.0 31.0 1,559 $1,146 36.0 36.0 %Collaboration revenues 114 64 80.7 80.7 306 175 75.4 75.4 %Total $688 $501 37.3 37.3 1,865 $1,321 41.2 41.2 %HCV United States $60 $76 (19.5 19.5 124 $288 (56.6 56.6 International 216 302 (28.7 29.8 640 923 (30.7 30.5 Total $276 $378 (26.8 27.7 764 $1,211 (36.9 36.7 Lupron United States $161 $155 4.1 4.1 488 $485 0.6 0.6 %International 40 38 3.5 1.6 117 117 (0.1 0.5 Total $201 $193 4.0 3.6 605 $602 0.5 0.4 %Creon United States $215 $187 14.8 14.8 596 $517 15.3 15.3 %Synagis International $116 $96 21.0 23.5 456 $460 (0.8 1.7 Synthroid United States $191 $188 1.5 1.5 576 $558 3.1 3.1 %AndroGel United States $147 $174 (14.9 14.9 437 $501 (12.7 12.7 Kaletra United States $16 $27 (39.2 39.2 54 $90 (39.9 39.9 International 69 110 (38.2 40.4 256 326 (21.7 24.3 Total $85 $137 (38.4 40.2 310 $416 (25.7 27.7 Sevoflurane United States $19 $19 0.5 0.5 56 $58 (2.4 2.4 International 81 83 (3.4 3.3 255 269 (5.5 3.8 Total $100 $102 (2.7 2.6 311 $327 (4.9 3.5 Duodopa United States $16 $10 56.4 56.4 44 $26 70.8 70.8 %International 78 64 21.5 16.6 211 189 11.7 12.3 %Total $94 $74 26.3 22.0 255 $215 18.7 19.2 %All $181 $342 (46.9 47.4 767 $928 (17.4 17.1 Total net revenues $6,995 $6,432 8.8 8.1 20,477 $18,842 8.7 8.8 %The following discussion analysis AbbVie net revenues product presented constant currency basis.Global HUMIRA sales increased 15 three nine months ended September 30 2017 primarily result market growth across therapeutic categories geographies well favorable pricing certain geographies In United States HUMIRA sales increased 19 three months 20 nine months ended September 30 2017 driven market growth across indications favorable pricing Internationally HUMIRA sales increased 7 three nine months ended September 30 2017 driven primarily market growth AbbVie continues pursue strategies intended differentiate HUMIRA competing products add sustainability future growth HUMIRA.2017 Form 10-Q 30Net revenues IMBRUVICA represent product revenues United States collaboration revenues outside United States related AbbVie 50 share IMBRUVICA profit Global IMBRUVICA sales increased 37 three months 41 nine months ended September 30 2017 result continued penetration IMBRUVICA first-line treatment patients chronic lymphocytic leukemia CLL well favorable pricing.Global HCV sales decreased 28 three months 37 nine months ended September 30 2017 result market contraction lower market share price erosion VIEKIRA These factors partially offset launch MAVYRET certain geographies third quarter 2017.Net revenues Creon increased 15 three nine months ended September 30 2017 driven primarily continued market growth higher market share Creon maintains market leadership pancreatic enzyme market.Synagis seasonal product majority sales occurring first fourth quarters Synagis revenues increased 23 three months ended September 30 2017 primarily due seasonal acceleration certain geographies tender timing Synagis revenues nine months ended September 30 2017 decreased 2 Net revenues Duodopa increased 22 three months 19 nine months ended September 30 2017 primarily result market penetration geographic expansion Gross Margin Three months endedSeptember 30 Nine months endedSeptember 30 dollars millions 2017 2016 change 2017 2016 changeGross margin $5,379 $4,928 9 15,717 $14,564 8%as net revenues 77 77 77 77 Gross margin percentage net revenues flat three nine months ended September 30 2017 compared prior year Gross margin percentage three nine months ended September 30 2017 favorably impacted product mix operational efficiencies offset unfavorable impact higher intangible asset amortization IMBRUVICA profit sharing arrangement.Selling General Administrative Three months endedSeptember 30,Nine months endedSeptember 30 dollars millions 2017 2016 change20172016 changeSelling general administrative 1,452 $1,381 5 4,324 $4,202 3%as net revenues 21 21 21 22 SG&A expenses percentage net revenues flat three months decreased nine months ended September 30 2017 compared prior year SG&A expense percentage three nine months ended September 30 2017 favorably impacted continued leverage revenue growth partially offset new product launch expenses SG&A expense percentage nine months ended September 30 2017 also unfavorably impacted litigation reserve charges 97 million.2017 Form 10-Q 31Research Development Acquired In-Process Research Development Three months endedSeptember 30 Nine months endedSeptember 30 dollars millions 2017 2016 change 2017 2016 changeResearch development $1,222 $1,106 11 3,580 $3,176 13 %as net revenues 17 17 17 17 Acquired in-process research development 80 (100 15 $160 (91 Research Development R&D expenses three nine months ended September 30 2017 increased compared prior year principally due increased funding support company emerging mid late-stage pipeline assets impact post-acquisition R&D expenses Stemcentrx Boehringer Ingelheim BI compounds These increases partially offset lower acquisition related costs decreased 54 million three months 130 million nine months ended September 30 2017 compared prior year Acquired in-process research development IPR&D expenses reflect upfront payments related various collaborations There individually significant transactions cash flows three nine months ended September 30 2017 2016.Other Non-Operating Expenses Three months endedSeptember 30 Nine months endedSeptember 30 millions 2017 2016 2017 2016Interest expense $293 $271 $851 $731Interest income (41 21 99 56)Interest expense net $252 $250 $752 $675 Net foreign exchange loss gain 9 4 28 $313Other expense net 349 101 484 152Interest expense net flat three months ended September 30 2017 compared prior year The increase nine months ended September 30 2017 compared prior year primarily due May 2016 issuance 7.8 billion aggregate principal amount senior notes issued finance acquisition Stemcentrx repay outstanding term loan.Net foreign exchange loss nine months ended September 30 2016 included losses totaling 298 million related devaluation AbbVie net monetary assets denominated Venezuelan bolivar See Note 8 Condensed Consolidated Financial Statements additional information regarding Venezuelan devaluation.Other expense net included charges related changes fair value BI Stemcentrx contingent consideration liabilities totaled 401 million three months 547 million nine months ended September 30 2017 compared 104 million three months 145 million nine months ended September 30 2016 following initial recognition liabilities second quarter 2016 The fair value contingent consideration liabilities impacted passage time multiple inputs including probability success achieving regulatory/commercial milestones discount rates market-based factors For three nine months ended September 30 2017 change fair value represented mainly higher probabilities success passage time See Note 4 Condensed Consolidated Financial Statements additional information regarding acquisitions Stemcentrx BI compounds Other expense net also included realized gains available-for-sale investment securities 39 million three months 49 million nine months ended September 30 2017.2017 Form 10-Q 32Income Tax ExpenseThe effective tax rate 22 three months 20 nine months ended September 30 2017 21 three months 22 nine months ended September 30 2016 The effective tax rate period differed statutory tax rate principally due benefit foreign operations reflects impact lower income tax rates locations outside United States tax exemptions incentives Puerto Rico foreign tax jurisdictions business development activities together cost repatriation decisions The change effective tax rate three nine months ended September 30 2017 prior year principally due changes jurisdictional mix earnings well certain discrete factors events including collaborations impact prior year non-deductible devaluation loss related Venezuela impact adoption ASU No 2016-09 changed accounting treatment excess tax benefits associated stock-based awards See Note 1 Condensed Consolidated Financial Statements additional information related adoption accounting pronouncement.FINANCIAL POSITION LIQUIDITY AND CAPITAL RESOURCES Nine months endedSeptember 30 millions)2017 2016Cash flows provided used Operating activities$7,376 $5,500Investing activities(475 5,955)Financing activities(3,584 1,426)Operating cash flows nine months ended September 30 2017 reflected improved results operations resulting revenue growth improvement operating earnings well favorability timing income tax payments compared prior year Cash provided operating activities reflected AbbVie voluntary contributions principal domestic defined benefit plan 150 million nine months ended September 30 2017 2016 Realized excess tax benefits associated stock-based compensation totaled 53 million nine months ended September 30 2017 presented within cash flows operating activities result adoption new accounting pronouncement In nine months ended September 30 2016 prior adoption new accounting pronouncement realized excess tax benefits 47 million presented within cash flows financing activities See Note 1 Condensed Consolidated Financial Statements additional information regarding adoption new accounting pronouncement.Investing cash flows nine months ended September 30 2017 included net sales maturities investment securities totaling 52 million For nine months ended September 30 2016 investing activities primarily included 1.9 billion cash consideration paid acquire Stemcentrx June 2016 595 million upfront payment acquire certain BI compounds April 2016 net purchases investment securities totaling 2.9 billion Cash flows investing activities nine months ended September 30 2017 2016 also reflected capital expenditures acquisitions investments.Financing cash flows included cash dividend payments 3.1 billion nine months ended September 30 2017 2.8 billion nine months ended September 30 2016 The increase cash dividend payments driven increase quarterly dividend rate 0.57 per share 0.64 per share beginning dividend paid February 2017 On September 8 2017 board directors declared quarterly cash dividend 0.64 per share stockholders record close business October 13 2017 payable November 15 2017 On October 27 2017 company announced board directors declared increase company's quarterly cash dividend 0.64 per share 0.71 per share beginning dividend payable February 15 2018 stockholders record January 12 2018 This reflects increase approximately 11 previous quarterly rate The timing declaration amount payment dividends within discretion board directors depend upon many factors including AbbVie financial condition earnings capital requirements operating subsidiaries covenants associated certain AbbVie debt service obligations legal requirements regulatory constraints industry practice ability access capital markets factors deemed relevant board directors.On February 16 2017 AbbVie's board directors authorized 5.0 billion increase AbbVie's existing stock repurchase program Under program company repurchased approximately 7.8 million shares 500 million open market nine months ended September 30 2017 Additionally nine months ended September 30 2017 AbbVie cash-settled 285 million open market purchases made end 2016 The stock repurchase authorization permits purchases AbbVie 2017 Form 10-Q 33shares time time open-market private transactions management's direction depending company's cash flows net debt level market conditions The program time limit discontinued time.During nine months ended September 30 2017 2016 company issued redeemed commercial paper The balance commercial paper outstanding 800 million September 30 2017 377 million December 31 2016 AbbVie may issue additional commercial paper retire commercial paper meet liquidity requirements needed In May 2016 company issued 7.8 billion aggregate principal amount senior notes Approximately 2.0 billion net proceeds used repay outstanding term loan due mature November 2016 approximately 1.9 billion net proceeds used finance acquisition Stemcentrx approximately 3.8 billion net proceeds used finance accelerated share repurchase agreement.In third quarter 2017 AbbVie paid 305 million contingent consideration BI related Phase 3 enrollment milestone 268 million milestone included financing cash flows 37 million included operating cash flows nine months ended September 30 2017.Cash equivalents impacted net favorable exchange rate changes totaling 29 million nine months ended September 30 2017 net unfavorable exchange rate changes totaling 300 million nine months ended September 30 2016 The unfavorable exchange rate changes 2016 primarily due devaluation AbbVie net monetary assets denominated Venezuelan bolivar While significant portion cash equivalents September 30 2017 considered reinvested indefinitely foreign subsidiaries AbbVie expect reinvestment affect liquidity capital resources If funds needed operations United States AbbVie would required accrue pay U.S income taxes repatriate funds AbbVie believes sufficient sources liquidity support assumption amount undistributed earnings September 30 2017 reinvested indefinitely.Credit RiskAbbVie monitors economic conditions creditworthiness customers government regulations funding domestically abroad AbbVie regularly communicates customers regarding status receivable balances including payment plans obtains positive confirmation validity receivables AbbVie establishes allowance accounts receivable probable collected AbbVie may also utilize factoring arrangements mitigate credit risk although receivables included arrangements historically significant amount total outstanding receivables.AbbVie continues business foreign governments certain countries including Greece Portugal Italy Spain historically experienced challenges credit economic conditions Substantially AbbVie trade receivables Greece Portugal Italy Spain government health systems Outstanding governmental receivables countries net allowances doubtful accounts totaled 246 million September 30 2017 244 million December 31 2016 The company also continues business foreign governments certain oil-exporting countries recently experienced deterioration economic conditions including Saudi Arabia Russia may result delays collection receivables Outstanding governmental receivables related Saudi Arabia net allowances doubtful accounts 141 million September 30 2017 122 million December 31 2016 Outstanding governmental receivables related Russia net allowances doubtful accounts 142 million September 30 2017 110 million December 31 2016 Global economic conditions customer-specific factors may require company periodically re-evaluate collectability receivables company could potentially incur credit losses.Currently AbbVie believe economic conditions oil-exporting countries significant impact company liquidity cash flow financial flexibility However government funding become unavailable countries significant adverse changes reimbursement practices occur AbbVie may able collect entire balance outstanding September 30 2017.2017 Form 10-Q 34Credit Facility Access Capital Credit RatingsCredit FacilityAbbVie currently 3.0 billion five-year revolving credit facility matures October 2019 The revolving credit facility enables company borrow funds unsecured basis variable interest rates contains various covenants At September 30 2017 company compliance credit facility covenants Commitment fees credit facility insignificant There amounts outstanding credit facility September 30 2017 December 31 2016.Access CapitalThe company intends fund short-term long-term financial obligations mature cash hand future cash flows operations issuing additional debt The company ability generate cash flows operations issue debt enter financing arrangements acceptable terms could adversely affected material decline demand company products solvency customers suppliers deterioration company key financial ratios credit ratings material unfavorable changes business conditions At current time company believes sufficient financial flexibility issue debt enter financing arrangements attract long-term capital acceptable terms support company growth objectives.Credit RatingsThere changes company credit ratings nine months ended September 30 2017 Unfavorable changes ratings may adverse impact future financing arrangements however would affect company ability draw credit facility would result acceleration scheduled maturities company outstanding debt CRITICAL ACCOUNTING POLICIESA summary company significant accounting policies included Note 2 entitled Summary Significant Accounting Policies company Annual Report Form 10-K year ended December 31 2016 There significant changes company application critical accounting policies nine months ended September 30 2017.FORWARD-LOOKING STATEMENTSSome statements quarterly report Form 10-Q may forward-looking statements purposes Private Securities Litigation Reform Act 1995 The words believe expect anticipate project similar expressions among others generally identify forward-looking statements AbbVie cautions forward-looking statements subject risks uncertainties may cause actual results differ materially indicated forward-looking statements Such risks uncertainties include limited challenges intellectual property competition products difficulties inherent research development process adverse litigation government action changes laws regulations applicable industry Additional information economic competitive governmental technological factors may affect AbbVie operations set forth Item 1A Risk Factors AbbVie Annual Report Form 10-K year ended December 31 2016 filed Securities Exchange Commission AbbVie notes factors investors permitted Private Securities Litigation Reform Act 1995 AbbVie undertakes obligation release publicly revisions forward-looking statements result subsequent events developments except required law.ITEM 3 QUANTITATIVE AND QUALITATIVE